Uterine Perforation on Invasive Hydatidiform Mole during EMACO Treatment

Bram Pradipta, Andrijono, Sigit Purbadi, Tofan W Utami

Abstract

Objective: Improving skill and knowledge to recognize and manage a rare case of uterine perforation on invasive hydatidiform mole.

Method: Case report.

Result: A 42 years old Indonesian woman, Parity 2 Abortus 2 with history of 2 c-sections and 2 curettages, came with chief complaint of recurrent vaginal bleeding since 4 months before admission. Patient had a history of previous curettage with indication of hydatidiform mole and recurrent bleeding with no histopathology results. On examination we found a vesicular mass with infiltration, destroying mole and recurrent bleeding with no histopathology results. On examination we found a vesicular mass with infiltration, destroying mole and recurrent bleeding. Chest x-ray showed multiple nodules in the lung. The patient, considered as low risk Gestational Trophoblastic Neoplasia patient with FIGO Score of 6, underwent chemotherapy with 2 series of methotrexate. Due to the non-declining level of -hCG, the regimen was added with EMACO. In the process of chemotherapy, the patient's -hCG declined but then she complained of major abdominal pain. Exploratory laparotomy was performed and we found a mass sized 5x5x5 cm on the right side of the uterus at the broad ligament with a rupture at the posterior part of the mass sized 0.5x0.5 cm. Upon incision of the uterus, we found a mass from the right side protruding to the isthmus of the uterus. Histopathology showed necrosis, blood and chorionic villi in myometrium corresponding to invasive mole. Patient was then given another 5 series of EMACO and her condition was unremarkable during the remaining course of treatment.

Conclusion: Invasive mole treatment is determined based on the risk factors. Uterine perforation still occurred in this case regardless of the decreasing hCG level during EMACO treatment. It emphasizes the importance of clinical examination as chemotherapy responsiveness. Long-term treatment can have a good prognosis but good collaboration between the gynecologist and the patient is essential.

Keywords: EMACO, invasive mole, perforation

Abstrak

Tujuan: Meningkatkan pengetahuan dan kemampuan untuk menangani dan menangani kasus perforasi uterus pada mola hidatidosa invasif.

Metode: Laporan kasus.

Hasil: Seorang perempuan berusia 42 tahun, Paritas 2 Abortus 2 dengan riwayat 2 seksio sesarea dan 2 kuretase, datang dengan keluhan utama perdarahan perevaginum berulang sejak 4 bulan sebelumnya. Pasien memiliki riwayat kuretase sebelumnya atas indikasi mola hidatidosa dan perdarahan berulang tanpa ditemukan hasil histopatologi. Pada pemeriksaan kami menemukan massa vesikular dengan indikasi mola hidatidosa dan perdarahan. Pada pemeriksaan pemeriksaan dengan 2 seri metotrexat. Karena kadar -hCG yang tidak turun, kemoterapi di tambah dengan EMACO. Dalam proses kemoterapi, kadar -hCG turun tapi kemudian pasien mengalami keluhan nyeri perut yang berat. Laparotomi dilakukan dan ditemukan massa berukuran 5 x 5 x 5 cm di sisi rahim tepat pada ligamentum uteri, serta massa dalam miometrium berukuran 0,5 x 0,5 cm. Pada tahap ini massa dioperasi sebelumnya, hasil histopatologi menunjukkan bagian nekrosis, darah dan villi korialis. Hasil kemoterapi selama 5 siklus dengan kondisi baik selama jangka waktu pengobatan.

Kesimpulan: Pengobatan mola invasif dikelompokkan tergantung faktor risiko untuk menentukan tatalaksana. Perforasi uterus masih terjadi dalam kasus ini meskipun tingkat hCG turun menurut hasil pengobatan EMACO. Hal tersebut menekankan pentingnya pemeriksaan klinis dalam menilai respons kemoterapi. Tatalaksana bisa dilakukan jangka panjang dengan prognosis yang baik dengan kerja sama yang baik antara dokter dan pasien.

Kata kunci: EMACO, mola invasif, perforasi

INTRODUCTION

Gestational trophoblastic diseases are a heterogeneous group of conditions ranging from the benign hydatidiform mole to the malignant choriocarcinoma with complete hydatidiform mole occurring in around 1 per 1,000 conceptions. Invasive mole is a condition where a molar pregnancy, such as a partial hydatidiform mole or complete hydatidiform mole, invades the wall of the uterus, potentially spreading and metastasizing to other parts of...
the body. It comprises only about 5-8% of all gestational trophoblastic neoplasia (GTN). Here we present a case of an Indonesian woman with uterine perforation because of invasive mole in the process of undergoing chemotherapy with methotrexate and even with EMACO.

CASE ILLUSTRATION

History, Examination and Management

We report a case of a 42-years old Indonesian woman who came to our hospital with chief complaint of recurrent vaginal bleeding since 4 months prior to admission. Patient had a history of two prior curettage in other hospital, 4 months and 2 months before, with indication of hydatidiform mole and recurrent bleeding, respectively. Unfortunately no tissues were checked for pathology examination. Patient's obstetric history included 2 cesarean sections and 2 curettage on her previous pregnancies.

On physical examination, we found the patient's condition to be unremarkable. On gynecological examination we found that the uterus was enlarged with suspected adnexal mass on the right adnexa. On ultrasonography we found a vesicular mass that infiltrated and destroyed the right-front uterine corpus, sized 8x6 cm with an internal echo mass, blood like structure inside. Chest x-ray showed multiple nodules in the lung.

The patient was then considered as low risk GTN patient with FIGO Score of 6. She then underwent chemotherapy with two series of methotrexate. The baseline hCG level was 99,947 IU/ml. After the first methotrexate, it decreased to 58,000 IU/ml but then increased to 69,100 IU/ml after the second dose. Because of that, the regimen was added with EMACO. After the 1st EMACO, the patient's hCG declined to 11,854 IU/ml but then she complained of major abdominal pain. We then performed an exploratory laparotomy and found a mass sized 5x5x5 cm in the right side of the uterus at the broad ligament with a rupture at the posterior part of the mass sized 0.5x0.5 cm. Both of the tubes and ovaries were within normal limits. Upon incision of the uterus, we found a mass from the right side protruding to the isthmus of the uterus.

Patient was then given another 5 series of EMACO and hCG continued to decline to as low as 1.45 IU/ml. The patient's condition was unremarkable during the remaining course of treatment.

Figure 1. Ultrasonography results: Malignant Trophoblastic that Invades the Right Uterine Corpus and Adnexa.

Figure 2. Intraoperative Finding Showing Mass with a Rupture at the Posterior Part.
DISCUSSION

Invasive mole is a condition where a molar pregnancy, such as a partial hydatidiform mole or complete hydatidiform mole, invades the wall of the uterus, potentially spreading and metastasizing to other parts of the body (such as the vagina or lungs).\textsuperscript{2,4,5} Its clinical characteristic are heterogeneous.\textsuperscript{4} Untreated invasive moles tend to invade the uterine wall locally, which can result in uterine perforation and hemorrhage.\textsuperscript{6-8} It is characterized by the persistence of edematous chorionic villi with trophoblastic proliferation invading into the myometrium.\textsuperscript{9} The presence of villi in the trophoblastic tissue differentiates an invasive mole from choriocarcinoma.\textsuperscript{3,9,10}

GTN is considered the most curable gynecologic malignancy.\textsuperscript{11} The management of low-risk metastatic GTN are similar to that of non-metastatic with very good response of single agent chemotherapy and those who fail can be treated with alternative single agent or combination chemotherapy.\textsuperscript{5} Our patient had a FIGO score of 6 and was considered as low risk GTN. Data from a single center showed that patients with a low-risk FIGO score but with an hCG value exceeding 100,000 mIU/ml frequently require combination chemotherapy.\textsuperscript{12} The failure of treatment with methotrexate increased the score to 8 in our patient and she was then considered as high risk. Chemoresistant case is when the patient had a plateau (<50% fall in the -hCG levels) or an increased -hCG level and/or development of new metastases for at least two consecutive cycles of combined chemotherapy.\textsuperscript{13}

EMACO has the best effectiveness-to-toxicity ratio, hence making it the first line regimen of combination chemotherapy.\textsuperscript{14} Patients with disease resistant to EMACO can be treated using EMAEP, a regimen that substitutes cyclophosphamide and vincristine on day 8 with cisplatin and etoposide.\textsuperscript{14} Our patient had a lowered -hCG level from 69,000 to 11,000 in the EMACO process, but clinically the patient had abdominal pain that was later shown as a uterine perforation. Serum hCG level is the most relevant parameter in GTN detection as well as in checking the efficacy of administered therapy.\textsuperscript{15} In our case, -hCG levels seem to respond to the chemotherapy with the decreasing level but uterine perforation still occurred, which emphasized the importance of clinical examination to assess chemotherapy responsiveness. Chemoresistance may not be the case for our patient. Other regimens that were also effective in treating high-risk refractory GTN includes BEP (bleomycin, etoposide, cisplatin), ICE (ifosfamide, carboplatin, etoposide), VIP (etoposide, ifosfamide, cisplatin) and also FAEV (fluorouridine, dactinomycin, etoposide, and vincristine).\textsuperscript{14,16} Patients with chemoresistant GTN have a bad prognosis and worse outcome compared with patients with relapsed GTN.\textsuperscript{13}

As far as we know, there have not been any case reports on cesarean scar site of invasive mole. There are no clear guidelines for the management of cesarean scar site molar pregnancy. Current literature reveals ultrasound-guided suction evacuation to be the most widely used method and the most successful.\textsuperscript{17} Moreover, some have advised use of oxytocin during curettage.\textsuperscript{18}

CONCLUSION

Invasive mole is a rare case with heterogenous presentation. Its treatment are grouped between the risk factor that should be counted beforehand to determine its therapy. The uterine perforation still occurred in this case despite the decreasing hCG level during EMACO treatment. It emphasizes the importance of clinical examination to assess
chemotherapy responsiveness. Long-term treat-
ment can yield good prognosis but good collabora-
tion between the gynecologist and the patient is
essential, as well as the need for support.

REFERENCES

1. Wolfberg AJ, Feltmate C, Goldstein DP et al. Low risk of re-
lapse after achieving undetectable HCG levels in women
with complete molar pregnancy. Obstet Gynecol 2004; 104:
551-4.
2. Kittur S, Venktesh, Ramlingappa A. A rare case of invasive
mole with silent uterine perforation. Int J Reprod Contra-
3. Abha S, Rohhaa R. Heterogenous Presentation of Chorio-
4. Singh S, Kaur N, Joshi S. Invasive mole presenting as pain
2(3): 480-1.
5. Ilancheran A. Optimal Treatment in Gestational Tropho-
blastic Disease. Ann Acad Med Singapore 1998; 27: 698-
704.
6. Chhabra S, Qureshi A. Gestational trophoblastic neoplasms
with special reference to invasive mole. Obstet Gynecol Ind
7. Kumar S, Vimala N, Mittal S. Invasive Mole Presenting as
8. RCOG. The Management of Gestational Trophoblastic Di-
9. Lurain JR. Gestational trophoblastic disease I: epidemiology,
pathology, clinical presentation and diagnosis of gestational
trophoblastic disease, and management of hydatidiform
10. Dollinger M, Rosenbaum Eh, Tempero M, Mulvihill S. Tro-
11. Burger RA, Creasman WT. Gestational Trophoblastic Neo-
12. McGrath S, Short D, Harvey R, Schmid P, Seckl MJ. The management and outcome of women with post-hy-
datidiform mole 'low-risk' gestational trophoblastic neo-
plasia, but hCG levels in excess of 100 000 IU. Br J Cancer
13. Feng F, Xiang Y, Wan X, Zhou Y. Prognosis of patients with
relapsed and chemo-resistant gestational trophoblastic neo-
plasia transferred to the Peking Union Medical College Hos-
14. May T, Goldstein DP, Berkowitz RS. Current chemo-
therapeutic management of patients with gestational tropho-
15. Tidy J, Gillespie AM, Bright N et al. Gestational trophoblastic
disease: a study of mode of evacuation and subsequent need
for treatment with chemotherapy. Gynecol Oncol 2000; 78:
309-12.
16. Feng F, Xiang Y, Wan X et al. Salvage combination chemo-
therapy with 5-fluorouracil, dactinomycin, etoposide, and vin-
cristine (FAEV) for patients with relapsed/chemoresistant
gestational trophoblastic neoplasia. Annals Oncol 2011;
22(7): 1588-94.
17. Kaluarachchi CI, Tissera AJ, Karunarathna SMGG. Caesarean
scar site complete molar pregnancy. Sri Lanka J Obstet Gy-
18. Jin FS, Ding DC, Wu GJ, Hwang KS. Molar pregnancy in a ce-